Ikpatt O F, Ndoma-Egba R
Department of Pathology, University of Turku, Kiinamyllnkatu 10, FIN-20520, Finland.
Cent Afr J Med. 2003 Nov-Dec;49(11-12):122-6.
Expression of oestrogen receptors (ER) and progesterone receptors (PR) in breast carcinomas identifies patients that are more likely to respond to adjuvant therapy.
Our aim was to evaluate the prevalence and prognostic value of histologically confirmed ER and PR immunoreactivity in breast carcinoma seen at Calabar, Nigeria.
Cross sectional study.
University of Calabar Teaching Hospital, Nigeria.
Sections of formalin-fixed, paraffin-embedded samples from 129 breast carcinomas were immunostained for ER and PR.
ER and PR were immunohistochemically detected in 24.0% and 13.9%, respectively, of the breast carcinomas. The staining results were significantly associated, though negatively, with the axillary lymph node status, clinical stage, and histological grade. In survival analysis of the whole material, neither ER nor PR positivity showed any prognostic value. In the premenopausal group, both ER and PR showed a prognostic potential. However, they had no independent prognostic value.
Further studies to assess the frequency and prognostic values of these hormone receptors in breast cancers, after standardized processing and a longer follow up period may be necessary to validate these findings. Furthermore, a consensus must be developed for scoring and reporting ER/PR in Nigerian material.
乳腺癌中雌激素受体(ER)和孕激素受体(PR)的表达可用于识别更可能对辅助治疗有反应的患者。
我们的目的是评估在尼日利亚卡拉巴尔所见乳腺癌中经组织学证实的ER和PR免疫反应性的患病率及预后价值。
横断面研究。
尼日利亚卡拉巴尔大学教学医院。
对129例乳腺癌的福尔马林固定、石蜡包埋样本切片进行ER和PR免疫染色。
在乳腺癌中,ER和PR的免疫组化检测阳性率分别为24.0%和13.9%。染色结果与腋窝淋巴结状态、临床分期和组织学分级显著相关,尽管呈负相关。在对整个样本的生存分析中,ER和PR阳性均未显示出任何预后价值。在绝经前组中,ER和PR均显示出预后潜力。然而,它们没有独立的预后价值。
可能需要进一步研究,在标准化处理和更长随访期后评估这些激素受体在乳腺癌中的频率和预后价值,以验证这些发现。此外,必须就尼日利亚样本中ER/PR的评分和报告达成共识。